Glucose substrate in the hydrogen breath test for gut microbiota determination: A recommended noninvasive test

Qi-Qi Xie, Jia-Feng Wang, Yang-Fen Zhang, Dong-Hui Xu, Bo Zhou, Ting-Hui Li, Zhi-Peng Li

Abstract
Intestinal dysbiosis and small intestinal bacterial overgrowth (SIBO) are common in patients with liver cirrhosis. Existing studies have not explored the association between gut dysbiosis and SIBO. We propose some suggestions for the authors’ experimental methods and concepts, and we hope these suggestions can be adopted. The hydrogen breath test is worthy of recommendation due to its high accuracy and convenient operation. We suggest changing the substrate of the hydrogen breath test from lactulose to glucose to improve the accuracy of each parameter. SIBO is a small subset of gut dysbiosis, and we propose clarifying the concept of both. SIBO may be caused by liver cirrhosis or one of the pathogeneses of gastrointestinal diseases. Therefore, interference from other gastrointestinal diseases should be excluded from this study.

Key Words: Glucose; Hydrogen breath test; Lactulose; Liver cirrhosis; Small intestinal bacterial overgrowth

Core Tip: The sensitivity of the hydrogen breath test is higher with glucose than lactulose as the substrate. We recommend using the hydrogen breath test in this experiment for measuring intestinal flora but replacing the test substrate with glucose. We recommend that the authors clarify the relation and concept of small intestinal bacterial overgrowth (SIBO) and gut dysbiosis. When exploring the relationship between gut dysbiosis and SIBO in cirrhosis, the etiology of SIBO should be considered. After estimating the sample size, we determined that the sample size included in the experiment was small and should be expanded.
TO THE EDITOR

The exact cause of intestinal dysbiosis and small intestinal bacterial overgrowth (SIBO) is unknown. However, studies have reported that SIBO is more common in patients with liver cirrhosis. Most of the existing studies focused only on the association between intestinal dysbiosis and various manifestations of liver cirrhosis, with few studying intestinal dysbiosis and/or SIBO alone. Recently, an original article by Maslennikov et al[1] published in the World Journal of Gastroenterology evaluated SIBO using a lactulose hydrogen breath test to explore the connection between gut dysbiosis and SIBO in patients with liver cirrhosis. Their findings suggest that gut flora disorder and SIBO are likely to be independent diseases of the gut microbiota in cirrhosis. We strongly agree with the authors’ point of view. Based on their research, we carried out further investigations and discussions. We put forward some suggestions for the authors’ experimental methods and hope they will be adopted.

At present, the gold standard for detecting SIBO is still small intestinal aspiration and quantitative culture[2,3]. However, there are obvious shortcomings, such as invasiveness to the human body and high detection costs. In addition, small intestinal aspiration and quantitative culture are prone to sampling errors. They may also result in distorted reports due to improper operation, and they have high professional and technical requirements for operators. Hydrogen breath testing is commonly used due to its high accuracy and ease of operation, providing a simple noninvasive and widely available diagnostic modality for suspected SIBO[5].

The accuracy of the hydrogen breath test could be improved if the test substrate were changed from lactulose to glucose. According to the study by Yao et al[4], we estimated the sample size of SIBO patients with liver cirrhosis (power and sample size calculation), and concluded that a sample value of about 400 cases is reasonable. However, the study sample of Maslennikov et al[1] had only 47 cases. For this reason, we consider the sample size to be too small. The impact on the experimental results may be more significant in studies with a small sample base if the test accuracy is not high enough. In that study, the assessment of SIBO is the premise and basis, and the accuracy of SIBO assessment would have affected the number of patients with liver cirrhosis detected with SIBO. This would have affected the parameters of bacterial abundance in the two sample groups, which would have further affected the researchers’ judgment on the experimental conclusions and analysis. Therefore, we believe that the hydrogen breath test with glucose as the substrate would have benefited that study.

Microbial dysbiosis refers to changes in the composition, density and function of gut microbes. The gut microbiome can be characterized by relative abundance and density and by the metabolites produced by microorganisms colonizing the mucosal lining of the gastrointestinal tract. SIBO is an example of intestinal disorder, traditionally defined as the presence of an excessive or abnormal microbiome in the proximal portion of the small intestine[5]. Conceptually, SIBO is a small part of gut dysbiosis[2,6], but the interaction and link between the two remain unclear. Whether SIBO can lead to the imbalance of microorganisms in other parts of the intestinal tract, and conversely, whether the imbalance of intestinal bacteria outside the small intestine can lead to SIBO, are worthy of further consideration and research.

Symptoms of SIBO are nonspecific, including bloating, diarrhea and gas formation, and may overlap with other gastrointestinal diseases[7-9]. SIBO has been implicated in the pathological process of various gastrointestinal diseases, for example, irritable entrails syndrome[2] and inflammatory bowel disease[5]. When exploring the relationship between intestinal flora in an imbalance state and SIBO in cirrhosis, the cause of SIBO should be considered. Since SIBO may also be caused by gastrointestinal diseases, interference from other gastrointestinal diseases should be excluded. If a patient with cirrhosis also has a gastrointestinal disease associated with SIBO, for instance, inflammatory bowel disease, the linkage among the three can become complicated and difficult to define. We recommend that investigators exclude confounding gastrointestinal diseases before grouping patients with cirrhosis with or without SIBO, and that patients should be grouped separately to see whether gastrointestinal disease has an effect on this study.

CONCLUSION

Hydrogen breath testing has higher accuracy and operability than small bowel aspiration and quantitative culture and is, therefore, more commonly used. The sensitivity of the hydrogen breath test
is higher with glucose than lactulose as the substrate. For this reason, we propose using the hydrogen breath test to measure the gut microbiota in this experiment and replace the test substrate with glucose. While SIBO is a small subset of gut dysbiosis, the interaction and relationship between the two are unclear. We recommend that the authors clarify the relationship and concept between the two. SIBO may be caused by pathogenesis of liver cirrhosis or by gastrointestinal diseases. For this reason, interference from other gastrointestinal diseases should be excluded from this study.

**FOOTNOTES**

**Author contributions:** Xie QQ Write the original draft; Wang JF was responsible for methodology and software; Zhang YF, Xu DH, Zhou B and Li TH analyzed data and wrote the original draft; Li ZP participated in conceptualization, writing, reviewing and editing; all authors participated in drafting the manuscript and all have read, contributed to, and approved the final version of the manuscript.

**Conflict-of-interest statement:** The authors have nothing to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Zhi-Peng Li 0000-0002-0355-7889

**S-Editor:** Wang DM

**L-Editor:** Kerr C

**P-Editor:** Wang DM

**REFERENCES**

1. Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Kudryavtseva A, Krasnov G. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis. *World J Gastroenterol* 2022; **28**: 1067-1077 [PMID: 35431497 DOI: 10.3748/wjg.v28.i10.1067]

2. Takakura W, Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. *Front Psychiatry* 2020; **11**: 664 [PMID: 32754066 DOI: 10.3389/fpsyg.2020.00664]

3. Saad RJ, Chey WD. Breath testing for small intestinal bacterial overgrowth: maximizing test accuracy. *Clin Gastroenterol Hepatol* 2014; **12**: 1964-72; quiz e119 [PMID: 24095975 DOI: 10.1016/j.cgh.2013.09.055]

4. Yao J, Chang L, Yuan L, Duan Z. Nutrition status and small intestinal bacterial overgrowth in patients with virus-related cirrhosis. *Asia Pac J Clin Nutr* 2016; **25**: 283-291 [PMID: 27222411 DOI: 10.6133/apjcn.2016.25.2.06]

5. Shah A, Holtmann G. Small intestinal bacterial overgrowth in inflammatory bowel disease. *Indian J Gastroenterol* 2022; **41**(1): 23-29 [PMID: 35031976 DOI: 10.1007/s12664-021-01235-y]

6. Ringel-Kulka T, Choi CH, Temas D, Kim A, Maier DM, Scott K, Galanko JA, Ringel Y. Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. *Am J Gastroenterol* 2015; **110**: 1339-1346 [PMID: 26303129 DOI: 10.1038/ajg.2015.220]

7. Achufusi TGO, Sharma A, Zamora EA, Manocha D. Small Intestinal Bacterial Overgrowth: Comprehensive Review of Diagnosis, Prevention, and Treatment Methods. *Cureus* 2020; **12**: e8860 [PMID: 32754400 DOI: 10.7759/cureus.8860]

8. Reding KW, Cain KC, Jarrett ME, Eugenio MD, Heitkemper MM. Relationship between patterns of alcohol consumption and gastrointestinal symptoms among patients with irritable bowel syndrome. *Am J Gastroenterol* 2013; **108**: 270-276 [PMID: 23295280 DOI: 10.1038/ajg.2012.414]

9. Diaz GA, Krivitzky LS, Mokhtarieni M, Rhead W, Bartley J, Feigenbaum A, Longo N, Berquist W, Berry SA, Gallagher R, Lichter-Konecki U, Bartholomew D, Harding CO, Cederbaum S, McCandless SE, Smith W, Vockley G, Bart SA, Korson MS, Kronn D, Zori R, Merritt JL 2nd, C S Nagamani S, Mauney J, Lemons C, Dickinson K, Moors TL, Coakley DF, Scharschmidt BF, Lee B. Ammonia control and neurocognitive outcome among urea cycle disorder patients treated with glycerol phenylbutyrate. *Hepatology* 2013; **57**: 2171-2179 [PMID: 22961727 DOI: 10.1002/hep.26058]
